Page last updated: 2024-12-06
tetrabutoxy titanium
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
tetrabutoxy titanium: RN given refers to monomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 21801 |
MeSH ID | M0167260 |
Synonyms (50)
Synonym |
---|
butyl alcohol, titanium(4+) salt |
butyl titanate(iv), (buo)4ti |
titanium tetrabutoxide |
tyzor tbt |
butyl titanate(iv) |
titanium, tetrabutoxy- |
titanic acid, tetrabutyl ester |
butyl orthotitanate |
titanium tetrabutylate |
nsc-59799 |
tyzor bp |
1-butanol, titanium(4+) salt |
tetrabutyl titanate |
titanium butoxide (ti(obu)4) |
titanium(iv) n-butoxide |
tetrabutyl orthotitanate |
5593-70-4 |
nsc-220232 |
hsdb 839 |
orgatics ta 25 |
butyl titanate monomer |
butyl titanate |
titanium(4+) butoxide |
titanium tetrakis(butoxide) |
nsc 59799 |
einecs 227-006-8 |
orthotitanic acid, tetrabutyl ester |
titanium butylate |
tetrabutoxy titanium |
titanium tetrabutanolate |
tetrabutyltitanate [czech] |
1-butanol titanium(4+) salt |
b 1 (titanate) |
nsc 220232 |
titanium butoxide |
tetrabutoxy titan |
B0742 |
9022-96-2 |
fjs8q2mx9i , |
unii-fjs8q2mx9i |
ec 227-006-8 |
1-butanol, titanium(4+) salt (4:1) |
tetrabutoxy titanium [hsdb] |
AKOS025243244 |
DTXSID6041262 |
orthotitanic acid tetrabutylester |
FT-0699968 |
Q4456610 |
4-(2,5-dimethyl-1h-pyrrol-3-yl)pyridine |
butan-1-olate;titanium(4+) |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (9)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 1 (11.11) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (22.22) | 29.6817 |
2010's | 6 (66.67) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.21
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.21) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 9 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |